Reinhard Dummer
0000-0002-2279-6906
Publication & Citation Trends
Publications
0 total
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma
Cited by 0
Semantic Scholar
Translating ctDNA into cutaneous melanoma care: an international expert survey
Cited by 0
Semantic Scholar
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors
Cited by 0
Semantic Scholar
Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
Cited by 0
Semantic Scholar
Pediatric Skin Cancer: Melanoma, Basal and Squamous Cell Carcinomas, and Dermatofibrosarcoma Protuberans
Cited by 0
Semantic Scholar
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma
Cited by 1
Semantic Scholar
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.
Cited by 6
Semantic Scholar
Research Topics
Melanoma and MAPK Pathways
(645)
Cutaneous Melanoma Detection and Management
(383)
CAR-T cell therapy research
(375)
Cancer Immunotherapy and Biomarkers
(352)
Immunotherapy and Immune Responses
(323)
Affiliations
AstraZeneca (United Kingdom)
Goethe University Frankfurt
Roche (Switzerland)
European Organisation for Research and Treatment of Cancer
Brigham and Women's Hospital